New cancer clinical trial: Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Published on: December 27, 2017 at 10:00AM
Conditions:   Neoplasms;   Prostate Cancer;   Lung Cancer;   Breast Cancer;   Colon Cancer
Interventions:   Biological: ETBX-051; adenoviral brachyury vaccine;   Biological: ETBX-061; adenoviral MUC1 vaccine;   Biological: ETBX-011; adenoviral CEA vaccine
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
http://ift.tt/2lbvIeY